Compare BGB & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | BGB | CTNM |
|---|---|---|
| Founded | 2012 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 488.8M | 550.7M |
| IPO Year | 2012 | 2024 |
| Metric | BGB | CTNM |
|---|---|---|
| Price | $11.12 | $9.57 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $21.43 |
| AVG Volume (30 Days) | 174.1K | ★ 596.9K |
| Earning Date | 01-01-0001 | 11-03-2026 |
| Dividend Yield | ★ 9.75% | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.85 | $6.73 |
| 52 Week High | $12.01 | $17.79 |
| Indicator | BGB | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 50.65 | 46.25 |
| Support Level | $10.98 | $8.59 |
| Resistance Level | $11.21 | $13.72 |
| Average True Range (ATR) | 0.09 | 0.77 |
| MACD | 0.01 | 0.23 |
| Stochastic Oscillator | 62.50 | 42.33 |
Blackstone Strategic Credit Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek high current income. The secondary objective of the fund is to seek the preservation of capital. Under normal market conditions, the Fund invests at least 80% of its Managed Assets in senior, secured floating-rate loans. The fund also invest in second-lien loans and high yield bonds and employs financial leverage, which may increase risk to the Fund. The Fund has a limited term and absent shareholder approval to extend the life of the Fund.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.